文献速递烧伤创面修复

万古霉素曲线下面积与谷浓度监测策略在烧伤或吸入性损伤患者中的多中心回顾性结局分析(MONITOR)

A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve Versus Trough-Based Dosing Strategies in Patients With Burn OR Inhalational Injuries (MONITOR).
PubMed 文献 · J Burn Care Res · 2024-01-01

MONITOR为多中心回顾性研究,纳入2017年1月1日至2022年8月31日13家烧伤中心收治的接受万古霉素治疗的热力或吸入性损伤患者485例、517个疗程,比较AUC监测与谷浓度监测的临床成功率及急性肾损伤(AKI)发生率。AUC监测组与仅谷浓度监测组临床成功率无差异;仅谷浓度监测组AKI发生率更高,但控制入院肾功能、慢性肾病病史及合并肾毒性药物后未达统计学显著。

要点

  • 485例患者共517个万古霉素疗程,按AUC监测或谷浓度监测分组比较临床成功率与AKI。
  • AUC监测组与仅谷浓度监测组临床成功率无差异。
  • 仅谷浓度监测组AKI发生率更高,但控制入院肾功能、慢性肾病病史及合并肾毒性药物后未达统计学显著。

核心结论

  • AUC监测与仅谷浓度监测的临床成功率无差异;仅谷浓度监测组AKI发生率更高,但控制入院肾功能、慢性肾病病史及合并肾毒性药物后未达统计学显著。

研究设计与样本

  • MONITOR为多中心回顾性研究,纳入2017年1月1日至2022年8月31日13家烧伤中心收治的接受万古霉素治疗的热力或吸入性损伤患者485例,共517个万古霉素疗程,按AUC监测或谷浓度监测分组。

主要发现

  • AUC监测组与仅谷浓度监测组临床成功率无差异。
  • 仅谷浓度监测组AKI发生率更高,但控制入院肾功能、慢性肾病病史及合并肾毒性药物后未达统计学显著。
  • 临床成功为复合定义,须同时不满足以下5项中任何1项:持续感染、复发、抗生素失败(临床恶化)、AKI、死亡。

关键数值与推荐

  • 美国感染病学会(IDSA)最新万古霉素治疗监测指南推荐使用AUC监测以最大化临床成功。
  • 临床成功为复合定义,须同时不满足以下5项中任何1项:持续感染、复发、抗生素失败(临床恶化)、AKI、死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vancomycin is a glycopeptide antibiotic that requires close therapeutic monitoring. Prolonged exposure to elevated concentrations increases risk for serious adverse effects such as nephrotoxicity. However, subtherapeutic concentrations may lead to bacterial resistance and clinical failure or death. The most recent Infectious Diseases Society of America publication regarding therapeutic monitoring of vancomycin recommends using area under the curve (AUC)-based monitoring to maximize clinical success. Despite the guideline recommendation for AUC-guided dosing, many institutions still use trough-only monitoring in their practices, including those caring for patients with acute burn injuries. Following burn injury, patients are at a higher risk for infections, multiorgan failure, and pharmacokinetic alterations. The primary objective of this multicenter retrospective study is to determine optimal therapeutic monitoring of vancomycin by comparing clinical success between AUC and trough-based monitoring in patients with burns. MONITOR was a multicenter, retrospective study of patients with thermal or inhalation injury admitted to one of 13 burn centers from January 1, 2017 to August 31, 2022 who received vancomycin. Demographic and clinical course data, including acute kidney injury (AKI) incidence and clinical success, were obtained. Patients were evaluated for clinical success and grouped according to method of monitoring and adjusting doses: AUC vs trough-based monitoring. Clinical success was a composite definition and lack of meeting any 1 of 5 criteria: (1) persistent infection, (2) relapse, (3) antibiotic failure (clinical worsening), (4) AKI, and (5) death. A total of 517 vancomycin courses were assessed from 485 patients. There was no difference in the rate of clinical success between AUC monitored and the trough-only monitored groups. Incidence of AKI was higher in the trough-only group; however, it was not statistically significant after controlling for renal function on admission, past medical history of chronic kidney disease, and concomitant nephrotoxins.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Santos RM, Boyd AN, Walroth TA, et al. A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve Versus Trough-Based Dosing Strategies in Patients With Burn OR Inhalational Injuries (MONITOR). J Burn Care Res. 2024. PMID: 38900835. doi:10.1093/jbcr/irae109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。